Houston regenerative medicine company expands lab for future trials

new digs

FibroBiologics has opened a new 10,000-square-foot Houston lab to scale up research efforts and pave the way for in-house manufacturing. Photo via Fibrobiologics.com

A Houston regenerative medicine company has unveiled new laboratory space with the goal of expanding its pioneering science.

FibroBiologics uses fibroblasts, the body’s most common type of cell, rather than stem cells, to help grow new cells. Fibroblasts are the primary variety of cells that compose connective tissue. FibroBiologics has found in studies that fibroblasts can be even more powerful than stem cells when it comes to both regeneration and immune modulation, meaning they could be a more versatile way forward in those fields.

In 2023, FibroBiologics moved into new lab space in the UH Technology Bridge. Now, with its new space, the publicly traded company, which has more than 240 patents issued or pending, will be even better equipped to power forward with its research.

The new space includes more than 10,000 square feet of space devoted to both labs and offices. The location is large enough to also house manufacturing drug product candidates that will be used in upcoming trials. Additionally, the company reports that it plans to hire additional researchers to help staff the facility.

“This expansion marks a transformative step forward for our company and our mission,” Pete O’Heeron, FibroBiologics founder and CEO, said in a news release. “By significantly increasing the size of our lab, we are creating the space and infrastructure needed to foster greater innovation and accelerate scientific breakthroughs.”

The streamlined, in-house manufacturing process will reduce the company’s reliance on external partners and make the supply chain simpler, O’Heeron added in the release.

Hamid Khoja, the chief scientific officer for FibroBiologics, also chimed in.

“To date, our progress in developing potentially transformative therapeutic candidates for chronic diseases using fibroblasts has been remarkable,” he added in the release. “This new laboratory facility will enable further expansion and acceleration of our research and development efforts. Additionally, the expansive new space will enable us to bring in-house currently outsourced projects, expand our science team and further contribute to the increased efficiency of our R&D efforts.”

This news arrives shortly after a milestone for the company in its research about neurodegenerative disease. Last month, fibroblast treatments in an animal model study demonstrated a notable regeneration of the myelin sheath, the layer that insulates nerves and is worn down by disease.

“Confirming remyelination in a second validated animal model is an important step in our research and development efforts, offering fresh hope for patients with demyelinating diseases, including multiple sclerosis,” O’Heeron added in a separate release. “These findings advance our mission to develop transformative fibroblast-based therapies that address the root causes of chronic disease, not just their symptoms, and reflect our dedication to pushing the frontiers of regenerative medicine."
From Your Site Articles
FibroBiologics will IPO this week. Photo via Getty Images

Houston regenerative medicine company to IPO, move toward more human trials

ready to list

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.”

O’Heeron was first exposed to the possibilities of fibroblasts as a means of regrowing discs in the spine. Since starting the company in 2008 as SpinalCyte, O’Heeron and FibroBiologics have organically written and filed more than 320 patents. Potential treatments go far beyond spinal surgery to include wound care, cancer, and multiple sclerosis.

According to O’Heeron, the goal in going public is to raise capital for human trials.

“We’ve had really fantastic results with animals and now we’re ready for humans,” he explained in September. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

FibroBiologics is growing with impressive speed. O’Heeron told us that he is hiring as quickly as he is able to find qualified scientists with the expertise to do the one-of-a-kind work required. The company opened a new lab last fall at the UH Technology Bridge, Newlin-Linscomb Lab for Cell Therapies. With its new status as a publicly traded company, FibroBiologics is primed to break even more ground.

FibroBiologics is opening a unique new lab at the University of Houston's Technology Bridge. Photo by Natalie Harms/InnovationMap

Houston regenerative medicine company opens new lab at UH

cell therapy innovation

Pete O’Heeron wants you to know that “Bohemian Rhapsody” was originally released as a B-side. What does this nugget about Queen have to do with regenerative medicine? For O’Heeron and his company, FibroBiologics, it means everything.

That’s because most scientists consider stem cells the A-side when it comes to the race to curing disease. But FibroBiologics has set its sights on fibroblasts. The most common cell in the body, fibroblasts are the main cell type in connective tissue.

“Everyone was betting on stem cells, and we started betting on fibroblasts,” says O’Heeron, who started the company in 2008 as SpinalCyte. “I think what we're going to see is that fibroblasts are going to end up winning, there are more robust, more that are lower cost cell, they have higher therapeutic values, higher immune modulation. They're just a better overall cell than the than the stem cells.”

Since a neurosurgeon and a dermatologist first introduced O’Heeron to the idea of using fibroblasts to regrow discs in the spine, the company has expanded its reach to include promising treatments for multiple sclerosis and cancer and in wound care. Imagine a world where doctors lay fibroblasts directly onto surgical incisions after surgery, cutting the time for healing in half.

FibroBiologics has organically written and filed more than 320 patents.

“It's quite a unique situation. I don’t think that in other areas of science that you have such a wide open area to go out and patent. It's just it was a brand new area nobody had been working on,” O’Heeron explains.

And soon, investors will be able to own a stake in the impressive work being forged in Houston. FibroBiologics, previously FibroGenesis, was formed in order to go public in a direct NASDAQ listing. The goal is to access the capital necessary to go to human trials. Earlier this year, the company also launched a crowdfunding campaign.

“We’ve had really fantastic results with animals and now we’re ready for humans,” says O’Heeron. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

With that in mind, the company just signed a deal with University of Houston’s Innovation Center. On Thursday, September 7, FibroBiologics will dedicate the Newlin-Linscomb Lab for Cell Therapies in the UH Technology Bridge. The new lab is named for former player and color commentator for the Houston Rockets, Mike Newlin and his wife, Cindy, as well as Pam and Dan Linscomb, a founding partner of Kuhl-Linscomb, one of the largest wealth management companies in Houston.

Other big local names newly attached to the company are astronaut Kate Rubins and Elizabeth Shpall, the director of the cell therapy laboratory at MD Anderson Cancer Center. Both have joined FibroBiologics as members of its scientific advisory board.

To fill the lab, O’Heeron says that he is adding to his team as quickly as he is able. The barrier is the fact that there are few, if any people in the world with the exact qualifications he’s seeking.

“Anytime you're breaking new scientific ground, you can't really just go out and recruit someone with that background because it really doesn't exist,” he says. But he is willing to teach and challenge scientists who are the right fit, and is hoping to expand the team in the new lab.

But like Queen did in 1975, FibroBiologics is pioneering a category of its own. And that’s something worth betting on.

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

Houston biopharma company launches equity crowdfunding campaign

money moves

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Astrodome group seeks new ideas for future of historic Houston landmark

8th Wonder News

The Astrodome may have once been touted as the Eighth Wonder of the World, but its current condition remains one of Houston's most famous follies. In an effort to find a better use for the iconic building, The Astrodome Conservancy has released a Request for Information (RFI), inviting proposals from interested parties on how the historic landmark might be used in the future. Respondents have until September 8 to submit their responses at the official conservancy site.

“This RFI is an opportunity for the market to help shape a shared vision for the Astrodome,” said Beth Wiedower Jackson, executive director of the Astrodome Conservancy, in a release. “We are looking to gather creative, feasible, and financially viable ideas that reflect both the significance of the Astrodome and its potential as a catalyst for future development.”

When the Astrodome opened in 1965, it was a marvel of engineering and the world's first air-conditioned, multi-purpose domed sports stadium. It remained an iconic part of Houston until changing trends in sports sent the Astros and the Houston Livestock Show and Rodeo to newer stadiums with modern amenities. After the 2003 rodeo, the dome was closed, except for a brief use as an evacuation shelter for Hurricane Katrina.

A decades-long fight over what to do with the Astrodome followed that closure. The City of Houston condemned the building for various code violations in 2009. Fully renovating it would cost over $700 million — a tall order for taxpayers. Demolishing it would be far cheaper (around $55 million), but its status on the National Register of Historic Places makes that virtually impossible. Meanwhile, Harris County pays hundreds of thousands of dollars a year to maintain the building.

Proposals for the space have run the gamut. In 2024, the Astrodome Conservancy proposed Vision: Astrodome, which would transform the building into an indoor mall and event space. That still appears to be the foundation of the plan according to the RFI.

The RFI is seeking private investment to partner with the Harris County property. Proposals are merely for planning purposes and will not automatically lead to contracts for development. Section 2.3 states that participants in the new mixed-use space will "require back-of-house infrastructure improvements to support reliable operations at scale," likely meaning that the plan is to fund some of the much-needed renovations via tenants. However, the RFI points out that participants in the revitalized Astrodome will also be eligible for historic space preservation tax credits.

While Vision: Astrodome seems committed to using the stadium as a public space for the entertainment of Houstonians, the RFI is clear other options are on the table.

The Astrodome possibly being used to house a data center is specifically mentioned, though the RFI mandates such a proposal would need to be very upfront about the infrastructure demands and continuing operating costs of such a project. Public backlash against data centers led to Governor Greg Abbott ordering a pause on grid connections to them pending further review.

"The Astrodome presents a unique opportunity for adaptive reuse and redevelopment that honors its legacy while positioning it for long-term community and economic impact," said the conservancy in the release announcing the RFI.

Houston lands $14M in latest CPRIT grants to advance cancer, lab-on-chip research

cancer funding

Thanks to a $4 million grant from the Cancer Prevention and Research Institute of Texas, the University of Houston has recruited a top-tier researcher developing AI-powered lab-on-a-chip technology for early cancer detection.

Tianhong Cui, a professor of mechanical engineering at the University of Minnesota Twin Cities and an adjunct professor of physiology and biomedical engineering at the Mayo Clinic, specializes in microelectromechanical systems and advanced manufacturing at microscale and nanoscale levels. In addition to lab-on-a-chip systems, Cui focuses on biosensors and water sensors.

Lab-on-a-chip devices deliver big results in a tiny package

The CPRIT grant supports Cui’s development of a microscale lab-on-a-chip system for early cancer detection and post-therapy monitoring.

“Lab-on-a-chip technology crams an entire lab’s worth of functions into a tiny device roughly the size of a USB stick,” according to Built In.

Common uses for the technology include medical diagnostics, point-of-care testing, and environmental monitoring.

Lab-on-a-chip work being carried out at UH and elsewhere in Houston promises to revolutionize cancer detection and treatment. For instance, Houston biotech company iBiochips, a spinout from the Houston Methodist Research Institute, makes lab-on-a-chip devices that bolster cancer detection and therapy.

Four local organizations gain $10 million in CPRIT grants

Four other Houston-area organizations received an additional $10 million in grants in CPRIT’s latest round of funding:

  • University of Texas MD Anderson Cancer Center received two $2 million grants to recruit researchers Zheqi Li of Harvard University’s Dana-Farber Cancer Institute and Nikolaos Koundouros of Weill Cornell Medicine.
  • Rice University received one $2 million grant to recruit researcher Maria Akoppyan, formerly of the University of Southern California.
  • UT Medical Branch at Galveston received one $2 million grant to recruit researcher Cristina Santarossa of Johns Hopkins University.
  • Houston-based biopharma company Pulmotect received one $2 million grant to support better outcomes for cancer patients by activating immunity in the lungs as a first line of defense against germs.

The funding was part of $35 million in new CPRIT grants for institutions and companies across Texas approved at the organization's most recent meeting. To date, CPRIT has awarded more than $4.2 billion in grants.

“These awards support research across the cancer continuum from prevention to new classes of therapeutics,” said Dr. Scott Hiebert, chief scientific officer of CPRIT, said in a news release. “The work of these investigators will impact the lives of Texans across the state.”

2 Houston high schools soar as America's best for 2026, says U.S. News

Honor Roll

Houston ISD's Carnegie Vanguard High School is standing tall as one of the 25 best high schools in America, according to U.S. News and World Report's 2026-2027 Best High Schools rankings.

DeBakey High School for Health Professions also ranks among the top 100 nationally, and 23 more Houston-area schools join them at the top of the class in Texas.

Each year, U.S. News evaluates approximately 27,000 public high schools on six factors: college readiness, college curriculum breadth, state assessment proficiency, state assessment performance, underserved student performance, and graduation rates.

The highest ranking public schools provide the best educational environments where "students demonstrated outstanding outcomes above expectations in math, reading and science state assessments, earned qualifying scores on an array of college-level exams, and graduated in high proportions."

"Every student deserves a pathway to success, and that journey often begins with selecting the right school," said LaMont Jones, Ed.D., managing editor for education at U.S. News. "The 2026-2027 Best High Schools rankings empower families with the valuable data and transparency they need to help make the best educational choices for them. We are proud to offer this essential resource to help shape the next generation of college-ready students."

Top ranking Houston schools
Carnegie Vanguard High School once again leads in Texas as the No. 2 best high school, and soared as No. 25 in U.S. News' national list of the best high schools, up from No. 42 last year.

DeBakey High School for Health Professions is the 9th best high school in Texas and ranks No. 91 nationally (down from No. 75 last year).

Three more local schools ranked among the best STEM schools in the country: Memorial High School in Spring Branch ISD (No. 86), Seven Lakes High School in Katy ISD (No. 96), and Dulles High School in Fort Bend ISD (No. 99).

In U.S. News' ranking of the best charter schools, four Houston-area schools made the top 100: Spring Branch ISD's Westchester Academy for International Studies (No. 62), Harmony School of Innovation - Katy (No. 72), Harmony School of Discovery - Houston (No. 78), and YES Prep - North Central (No. 100).

Other Houston-area schools that rank among the 100 best in Texas are:

  • No. 17 – Kerr High School, Alief ISD, Houston
  • No. 24 – Young Women's College Prep Academy, Houston ISD
  • No. 25 – Kinder High School for Performing and Visual Arts, Houston ISD
  • No. 31 – Challenge Early College High School, Houston ISD
  • No. 39 – Westchester Academy for International Studies, Spring Branch ISD, Houston
  • No. 44 – Tomball Star Academy, Tomball ISD
  • No. 45 – Harmony School of Innovation - Katy
  • No. 46 – North Houston Early College High School, Houston ISD
  • No. 51 – Eastwood Academy, Houston ISD
  • No. 52 – Seven Lakes High School, Katy ISD
  • No. 54 – Harmony School of Discovery - Houston
  • No. 55 – Energy Institute High School, Houston ISD
  • No. 56 – Spring Early College Academy, Spring ISD
  • No. 63 – Sharpstown International School, Houston ISD
  • No. 66 – YES Prep - North Central, Houston
  • No. 73 – Tompkins High School, Katy ISD
  • No. 76 – YES Prep - Southeast, Houston
  • No. 80 – Harmony School of Innovation - Sugar Land
  • No. 81 – Clements High School, Fort Bend ISD, Sugar Land
  • No. 82 – Houston Academy for International Studies, Houston ISD
  • No. 86 – Jordan High School, Katy ISD
  • No. 88 – Victory Early College High School, Aldine ISD, Houston
  • No. 96 – Clear Horizons Early College High School, Clear Creek ISD, Houston

---

This article originally appeared on CultureMap.com.

View All Listings